Cynvenio Biosystems ClearID Lung Cancer Test

Cynvenio Biosystems has launched its ClearID Lung Cancer blood test. The 11-gene panel leverages next-generation sequencing technology to identify tumor-related genetic mutations that can be treated with targeted therapies. It identifies ctDNA burden and detects somatic mutations as low as .13 percent with an accuracy of 99.76 percent and a sensitivity of 95.9 percent, the firm said.